Beta-lactam antibiotics play a pivotal role in addressing microbial threats, demonstrating versatility in treating a wide array of bacterial infections. Carbapenems, a potent subgroup, exhibit broad-spectrum activity against gram-positive and gram-negative bacteria, making them valuable in severe infections. Monobactams, such as aztreonam, are notable for their specificity against gram-negative aerobes, minimizing collateral damage to beneficial flora. Despite their efficacy, the emergence of beta-lactamases poses a challenge, prompting continuous research for novel compounds and combination therapies to combat resistance. The ongoing evolution of beta-lactam antibiotics underscores their significance in modern antimicrobial strategies.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain
Title : Gendered socioeconomic impacts of emerging infectious diseases: Insights from a mixed-methods study in Guinea
Stephanie Maltais, University of Montreal, Canada
Title : E2 ubiquitin-conjugating enzymes regulates dengue virus-2 replication in Aedes albopictus
Xueli Zheng, Southern Medical University, China